Phillip Prusinski
Family · Phoenix, AZNPI 1033661244
Payments from drug & device makers
Across 389 payments — averaging $21.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$2K
- Gilead$2K
- AbbVie$1K
- Merck$452
- Johnson & Johnson$360
- Novo Nordisk$334
- plus $2K from 18 others
What the payments were for
- Speaking & faculty fees$681%
- Food & beverage$8,15099%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 92 | $2,407 |
| Gilead | 123 | $2,117 |
| AbbVie | 47 | $1,029 |
| Merck | 19 | $452 |
| Johnson & Johnson | 24 | $360 |
| Novo Nordisk | 17 | $334 |
| AstraZeneca(2 entities) | 13 | $334 |
| Napo Pharmaceuticals Inc | 9 | $156 |
| Boehringer Ingelheim | 6 | $150 |
| Amgen | 8 | $146 |
| EMD Serono, Inc. | 6 | $143 |
| Janssen Scientific Affairs, LLC | 1 | $96 |
| Astellas Pharma US Inc | 3 | $94 |
| Lilly USA, LLC | 5 | $90 |
| Abbott | 4 | $78 |
| Theratechnologies Inc. | 2 | $68 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Medtronic | 2 | $29 |
| Dexcom, Inc. | 1 | $26 |
| Tolmar, Inc. | 1 | $20 |
| GSK | 1 | $17 |
| Bayer | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Acerus Pharmaceuticals Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,219 in reported general payments places this provider in the 95th percentile of 4,119 family providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 75 | $95,668 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 20 | $77,522 |
| FarxigaDapagliflozin Propanediol | 42 | $51,575 |
| JardianceEmpagliflozin | 52 | $48,507 |
| JulucaDolutegravir/Rilpivirine | 12 | $38,993 |
| OzempicSemaglutide | 30 | $35,448 |
| JanuviaSitagliptin Phosphate | 28 | $26,590 |
| TradjentaLinagliptin | 43 | $25,509 |
| DescovyEmtricitabine/Tenofov Alafenam | 12 | $23,905 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $21,586 |
| MyrbetriqMirabegron | 22 | $12,525 |
| LinzessLinaclotide | 15 | $10,804 |
| MounjaroTirzepatide | 11 | $10,756 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $10,678 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $7,544 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $90 | $106,42586 claims |
| GileadBiktarvy, Descovy | $2,117 | $101,42732 claims |
| Boehringer IngelheimJardiance, Tradjenta | $150 | $74,01595 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $334 | $62,25359 claims |
| Viiv Healthcare CompanyJuluca | $2,407 | $38,99312 claims |
| Novo NordiskOzempic | $334 | $35,44830 claims |
| MerckJanuvia | $452 | $26,59028 claims |
| GSKTrelegy Ellipta | $17 | $21,58621 claims |
| Astellas Pharma US IncMyrbetriq | $94 | $12,52522 claims |
| AbbVieLinzess, Synthroid | $1,029 | $11,40331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,119 family providers in Arizona.
Other family in Phoenix
- Kimberly HallaPhoenix$332K
- Audrey StevensonPhoenix$83K
- Rebekah EdwardsPhoenix$51K
- Tirsa QuartulloPhoenix$31K
- Jessica AcostaPhoenix$30K
- Stephanie JohnstonPhoenix$25K
- Kelly MarcelloPhoenix$23K
- Judith BergmanPhoenix$22K
- Lauren BonnerPhoenix$22K
- Rita GonzalezPhoenix$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.